SPATA2

Across TCGA pan-cancer cohorts, SPATA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPATA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where SPATA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	1.000	0.761	.005	20	view →
PDAC	DFS	Tertile	All	0.247	0.609	.002	17	view →
CCRCC	OS	Median	III,IV	0.759	0.899	.044	2	view →
GBM	DFS	Tertile	All	0.849	0.681	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA2–HNSC (DFS)

Open the HNSC breakdown →